The Role of Diverse Populations in US Clinical Trials

Leanne Woods-Burnham; Jabril R. Johnson; Stanley E. Hooker; Fornati W. Bedell; Tanya B. Dorff; Rick A. Kittles

doi:10.1016/j.medj.2020.12.009

The Role of Diverse Populations in US Clinical Trials

Leanne Woods-Burnham, Jabril R. Johnson, Stanley E. Hooker, Fornati W. Bedell, Tanya B. Dorff, Rick A. Kittles

Surgery

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Effective clinical trials are meant to provide the safest and fastest way to find new treatments to improve health. The FDA affirms that because people may respond differently to treatments, it is imperative to test drugs and medical products in a variety of populations (https://www.fda.gov/patients/clinical-trials-what-patients-need-know/basics-about-clinical-trials). Unfortunately, clinical trial enrollment in the US remains largely homogeneous, with the majority of participants being non-Hispanic white men. Despite efforts to increase diversity in recruitment for clinical trials, enrollment of racial/ethnic minorities in this nation has decreased over the past two decades.¹

Original language	English (US)
Pages (from-to)	21-24
Number of pages	4
Journal	Med
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/j.medj.2020.12.009
State	Published - Jan 15 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.medj.2020.12.009

Cite this

@article{c6d6dcc3277c44e8ae2154123bf01be0,

title = "The Role of Diverse Populations in US Clinical Trials",

abstract = "Effective clinical trials are meant to provide the safest and fastest way to find new treatments to improve health. The FDA affirms that because people may respond differently to treatments, it is imperative to test drugs and medical products in a variety of populations (https://www.fda.gov/patients/clinical-trials-what-patients-need-know/basics-about-clinical-trials). Unfortunately, clinical trial enrollment in the US remains largely homogeneous, with the majority of participants being non-Hispanic white men. Despite efforts to increase diversity in recruitment for clinical trials, enrollment of racial/ethnic minorities in this nation has decreased over the past two decades.1",

author = "Leanne Woods-Burnham and Johnson, {Jabril R.} and Hooker, {Stanley E.} and Bedell, {Fornati W.} and Dorff, {Tanya B.} and Kittles, {Rick A.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = jan,

day = "15",

doi = "10.1016/j.medj.2020.12.009",

language = "English (US)",

volume = "2",

pages = "21--24",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - The Role of Diverse Populations in US Clinical Trials

AU - Woods-Burnham, Leanne

AU - Johnson, Jabril R.

AU - Hooker, Stanley E.

AU - Bedell, Fornati W.

AU - Dorff, Tanya B.

AU - Kittles, Rick A.

PY - 2021/1/15

Y1 - 2021/1/15

N2 - Effective clinical trials are meant to provide the safest and fastest way to find new treatments to improve health. The FDA affirms that because people may respond differently to treatments, it is imperative to test drugs and medical products in a variety of populations (https://www.fda.gov/patients/clinical-trials-what-patients-need-know/basics-about-clinical-trials). Unfortunately, clinical trial enrollment in the US remains largely homogeneous, with the majority of participants being non-Hispanic white men. Despite efforts to increase diversity in recruitment for clinical trials, enrollment of racial/ethnic minorities in this nation has decreased over the past two decades.1

AB - Effective clinical trials are meant to provide the safest and fastest way to find new treatments to improve health. The FDA affirms that because people may respond differently to treatments, it is imperative to test drugs and medical products in a variety of populations (https://www.fda.gov/patients/clinical-trials-what-patients-need-know/basics-about-clinical-trials). Unfortunately, clinical trial enrollment in the US remains largely homogeneous, with the majority of participants being non-Hispanic white men. Despite efforts to increase diversity in recruitment for clinical trials, enrollment of racial/ethnic minorities in this nation has decreased over the past two decades.1

UR - http://www.scopus.com/inward/record.url?scp=85119619211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119619211&partnerID=8YFLogxK

U2 - 10.1016/j.medj.2020.12.009

DO - 10.1016/j.medj.2020.12.009

M3 - Article

AN - SCOPUS:85119619211

SN - 2666-6359

VL - 2

SP - 21

EP - 24

JO - Med

JF - Med

IS - 1

ER -

The Role of Diverse Populations in US Clinical Trials

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this